The company has launched the ad campaign with three patient ambassadors: Brian, Jeanette and Jennifer, each of whom is ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

BioMarin revealed topline results for the early-stage candidate, BMN 333, that suggest it is a “potentially superior version ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Thermo Fisher Scientific has implemented a string of layoffs in Carlsbad, California, in recent years, but it appears the ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

After Y-mAbs Therapeutics won its first FDA approval more than 4 years ago, the company has faced numerous hurdles on its quest to becoming an oncology powerhouse. | More than 4 years after its first ...

After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80 ...

In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a ...

As Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...